Research groups
Websites
-
MRC Molecular Haematology Unit
Research Unit
-
MRC Weatherall Institute of Molecular Medicine
Research Institute
DPhil projects available
Niche determinants required for leukaemic and normal stem cell function
Paresh Vyas
MRCP FRCP FRCPath
Professor of Haematology
- Consultant Physician
Our aim is to characterise the heterogeneous populations of leukaemia propagating cells in adult and childhood Acute Myeloid Leukaemia (AML) at functional, genetic, epigenetic and molecular levels, eventually at a single cell level, to improve our basic understanding of leukaemia initiation and propagation. The ultimate aim is to translate this knowledge to improve survival rates in patients.
Biography
Paresh Vyas is Professor of Haematology at the University of Oxford. He studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London, he did his PhD with Professor Doug Higgs and Professor Sir David Weatherall at the MRC Molecular Haematology Unit, Oxford. A three-year post-doctoral fellowship with Professor Stuart Orkin at Harvard University followed. He is a research-active Consultant Haematologist with a clinical practice in myeloid disorders: myelodysplastic syndrome, MDS, acute myeloid leukaemia, AML, and myeloproliferative disorders, MPD, as well as allogeneic stem cell transplant. His research in the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid stem cells. He studies single cell biology in normal and leukaemic haemopoiesis. He is on the UK AML and MDS clinical trial groups. He is co-Lead of the Oxford BRC Haematology and Stem Cells Theme, is on the Board of NHSBT, vice-chair of the MRC Clinical Training Panel and Translational Lead for the UK Therapy Acceleration Program.
Key publications
-
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Journal article
Quek L. et al, (2016), J Exp Med, 213, 1513 - 1535
-
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.
Journal article
Roberts I. et al, (2013), Blood, 122, 3908 - 3917
-
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.
Journal article
Goardon N. et al, (2011), Cancer Cell, 19, 138 - 152
Recent publications
-
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.
Journal article
Craddock C. et al, (2018), J Intern Med, 283, 371 - 379
-
From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.
Journal article
Jakobsen NA. and Vyas P., (2018), Clin Med (Lond), 18, s47 - s53
-
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Journal article
Schuurhuis GJ. et al, (2018), Blood, 131, 1275 - 1291
-
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.
Journal article
Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97
-
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
Journal article
Craddock CF. et al, (2017), Clin Cancer Res, 23, 6430 - 6440